Facing Indictment, GOP Rep. Chris Collins Won’t Seek Re-Election
The New York congressman says he will fill out his term but retracts his earlier vow to stay on the ballot. He faces charges of insider trading involving a biotechnology company.NEW YORK—In an about-face, U.S. Rep. Chris Collins is ending his re-election bid days after the Republican was charged with insider trading.
Collins released a statement Saturday morning saying he will suspend his campaign and fill out the rest of his term. Collins was indicted Wednesday on charges he used inside information about a biotechnology company to make illicit stock trades. He had said later that day he would remain on the ballot despite the indictment and fight the charges.
“I have decided that it is in the best interests of the constituents of NY-27, the Republican Party and President Donald Trump’s agenda for me to suspend my campaign for re-election to Congress,” the statement said.
He went on to say he will fill out his term and “continue to fight the meritless charges brought against me.” He has denied any wrongdoing.
Wednesday’s indictment charges Collins and two others, including his son, with conspiracy, wire fraud and other counts.
Prosecutors say the charges relate to a scheme to gain insider information about a biotechnology company headquartered in Sydney, Australia, with offices in Auckland, New Zealand.
Jessica Proud, a spokeswoman for the New York state Republican party, said no decision has been made about a possible replacement for Collins on the ballot. She said the party is weighing its options.
Your support matters…Independent journalism is under threat and overshadowed by heavily funded mainstream media.
You can help level the playing field. Become a member.
Your tax-deductible contribution keeps us digging beneath the headlines to give you thought-provoking, investigative reporting and analysis that unearths what's really happening- without compromise.
Give today to support our courageous, independent journalists.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.